National Review
Biden’s Travel Restrictions Don’t Follow the Science
Joe Biden never tires of saying his COVID-19 policies follow “the science.” He recently pontificated that he would battle the emerging Omicron coronavirus variant “with…
The New York Post
Politicians Are Using Omicron as an Excuse to Return to their Autocratic Ways
Since the start of the pandemic, governors around the country have often struggled to appear to be doing something to stem COVID-19, regardless of whether…
City Journal
One Size Doesn’t Fit All
In a rebuke of the Biden administration, the Fifth Circuit Court of Appeals reaffirmed its stay of the Occupational Safety and Health Administration’s (OSHA) workplace…
The New York Post
A Reality Check on How we Handle COVID-19 Risks
COVID-19 is still with us. Cases are rising in Europe and to a smaller extent in this country. But the fact that SARS-CoV-2, the virus…
National Review
Ending the Epidemic of Public-Nuisance Litigation
The opioid crisis has spawned a rash of litigation, with thousands of pending state and federal cases threatening to penalize legitimate prescription…
National Review
What’s Taking the FDA So Long on COVID Drug Molnupiravir?
On October 1, pharmaceutical companies Merck and Ridgeback Biotherapeutics announced that their investigational oral antiviral drug Molnupiravir reduced the risk of hospitalization or death…